Update of antibiotic trials for secondary prevention of coronary heart disease

By Anderson JL   Muhlestein JB  

Future Cardiology, Vol. 1, Iss. 2, 2005-03 ,pp. : 225-234

Future Medicine

Access to resources Recommend Favorite

The Lescol^® Intervention Prevention Study (LIPS): a double-blind, placebo-controlled, randomized trial of the long-term effects of fluvastatin after successful transcatheter therapy in patients with coronary heart disease

By Serruys Patrick WJC   de Feyter Pim J   Benghozi Renée   Hugenholtz Paul G   Lesaffre Emmanuel  

International Journal of Cardiovascular Interventions, Vol. 4, Iss. 4, 2001-12 ,pp. : 165-172

Informa Healthcare

Access to resources Recommend Favorite

Determinants of appropriate lipid management in patients with ischaemic heart disease. Cracovian Program for Secondary Prevention of Ischaemic Heart Disease

By Kawecka-Jaszcz K.   Jankowski P.   Pajak A.  

International Journal of Cardiology, Vol. 91, Iss. 1, 2003-09 ,pp. : 15-23

Elsevier

Access to resources Recommend Favorite

Design of ESPRIT: An International Randomized Trial for Secondary Prevention after Non-Disabling Cerebral Ischaemia of Arterial Origin

By  

Cerebrovascular Diseases, Vol. 10, Iss. 2, 2000-02 ,pp. : 147-150

Karger

Access to resources Recommend Favorite

Plasma amino-terminal pro-brain natriuretic peptide and accuracy of heart-failure diagnosis in primary care - A randomized, controlled trial

By Wright S.P.   Doughty R.N.   Pearl A.   Gamble G.D.   Whalley G.A.   Walsh H.J.   Gordon G.   Bagg W.   Oxenham H.   Yandle T.   Richards M.   Sharpe N.  

Journal of the American College of Cardiology, Vol. 42, Iss. 10, 2003-11 ,pp. : 1793-1800

Elsevier

Access to resources Recommend Favorite